结直肠癌（CRC）已成为一项重大的全球公共卫生挑战，由于其高发病率和死亡率，需要立即引起关注。定期CRC筛查对于早期发现癌前病变和CRC至关重要。：我们开发了一种新型表面增强拉曼散射（SERS）分析平台，采用高通量微阵列芯片作为载体和Au/SnO2纳米环阵列（Au/SnO2 NRAs） ）作为底物。该平台利用适配体识别-释放策略实现蛋白质肿瘤标志物的高效、灵敏检测。在检测过程中，适配体与目标蛋白之间的强亲和力和高特异性导致了原本与基底表面结合的SERS纳米探针的竞争性取代。结果，携带拉曼报告基因的SERS纳米探针被脱落，导致SERS信号强度降低。该平台表现出优异的检测性能，15分钟内完成快速检测，检测限（LOD）低至6.2× hnRNP A1 为 10-12 g/mL，S100P 为 6.51×10-12 g/mL。使用SERS平台分析的临床样本与酶联免疫吸附测定（ELISA）结果具有较高的一致性。该平台为结直肠癌癌前病变的早期检测、风险评估和治疗监测提供了有力支持，具有广泛的临床应用潜力。 © 2024 陈等人。

Colorectal cancer (CRC) has become a significant global public health challenge, demanding immediate attention due to its high incidence and mortality rates. Regular CRC screening is essential for the early detection of precancerous lesions and CRC.: We developed a novel surface-enhanced Raman scattering (SERS) analysis platform that employs high-throughput microarray chips as carriers and Au/SnO2 nanoring arrays (Au/SnO2 NRAs) as substrates. This platform utilizes an aptamer recognition-release strategy to achieve efficient and sensitive detection of protein tumor markers. In the detection process, the strong affinity and high specificity between the aptamer and the target protein result in competitive replacement of the SERS nanoprobes originally bound to the substrate surface. As a result, the SERS nanoprobes carrying Raman reporter genes are dislodged, leading to a reduction in the SERS signal intensity.The platform demonstrated excellent detection performance, with rapid detection completed within 15 minutes and limits of detection (LOD) as low as 6.2×10-12 g/mL for hnRNP A1 and 6.51×10-12 g/mL for S100P. Clinical samples analyzed using the SERS platform showed high consistency with enzyme-linked immunosorbent assay (ELISA) results.This platform offers strong support for the early detection, risk assessment, and treatment monitoring of colorectal cancer precancerous lesions, with broad potential for clinical applications.© 2024 Chen et al.